VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Targeting immune dysregulation in multiple myeloma

Tengteng Yu, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on targeting immune dysregulation in multiple myeloma, mentioning currently available therapies as well as novel targets that are currently being evaluated. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter